Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 17/20 | 1.00 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.57 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.57 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756580 | 0.85 | SIGMAR1 (0.74) | SIGMAR1SMYD2TP53CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5757385 | 0.85 | SIGMAR1 (0.74) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL5754393 | 0.84 | SIGMAR1 (0.72) | SIGMAR1SMYD2TP53CYP1A2CYP2D6 | |
| SCHEMBL16511553 | 0.84 | SIGMAR1 (0.83) | SIGMAR1 | |
| SCHEMBL5804316 | 0.82 | SIGMAR1 (0.93) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL16511184 | 0.82 | SIGMAR1 (0.80) | SIGMAR1CYP1A2CYP3A4 | |
| SCHEMBL27550763 | 0.80 | SIGMAR1 (0.65) | SIGMAR1SMYD2 | |
| SCHEMBL6961777 | 0.80 | SIGMAR1 (0.76) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL17476322 | 0.79 | SMYD2 (1.00) | SIGMAR1SMYD2TP53CYP1A2CYP2D6 | |
| SCHEMBL9019137 | 0.76 | SIGMAR1 (1.00) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379016-A1 | THERAPEUTICS AND METHODS OF TREATMENT OF ANGIOTENSIN-CONVERTING ENZYME 2 ASSOCIATED CONDITIONS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2021-12-09 | — | — | US | disclosed |
| WO-1992022279-A2 | N-[ARYLETHYL]-N-ALKYL-2-(1-PYRROLIDINYL)ETHYLAMINE DERIVATIVES FOR CNS DISORDERS | G.D. SEARLE & CO. (US) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379016-A1 | THERAPEUTICS AND METHODS OF TREATMENT OF ANGIOTENSIN-CONVERTING ENZYME 2 ASSOCIATED CONDITIONS | ACE2, ACE, AGTR2 | SIGMAR1 10/4885SMYD2 3068/4885TP53 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.